Results 121 to 130 of about 9,104 (252)

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016. [PDF]

J Psychopharmacol, 2021
Deen AA, Claridge H, Treble RD, Hamnett HJ, Copeland CS.   +4 more
europepmc   +1 more source

The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial

Addiction, EarlyView.
Abstract Background and aims Ketamine assisted psychotherapy is a promising new treatment for alcohol use disorder (AUD). The psychoactive effects of repeated intravenous (IV) ketamine infusions in people with AUD and their mechanistic role in treating AUD are largely unknown.
Cassie Bloy, Ananya Sarma, Bethan Marsh, Lorna Hardy, Meryem Grabski, Merve Mollaahmetoglu, Joshua Shotton, Shamhethan Bhaskaran, Anne Lingford‐Hughes, H. Val Curran, Celia Morgan, Will Lawn   +11 more
wiley   +1 more source

Application of Novel Psychoactive Substances: Chemsex and HIV/AIDS Policies Among Men Who Have Sex With Men in Hong Kong. [PDF]

Front Psychiatry, 2021
Chan ASW, Tang PMK.
europepmc   +1 more source

The prevalence of cannabidiol (CBD) use in North America and Europe: A meta‐analysis

Addiction, EarlyView.
Abstract Background and aims The global cannabidiol (CBD) market has expanded in recent years. Several studies suggest CBD use, whether for medical or recreational purposes, is on the rise; however, no systematic assessments of its prevalence have been conducted so far. This meta‐analysis aimed to estimate the prevalence of CBD use in North America and
Sara Weidberg, Clara Iza‐Fernández, Layla Alemán‐Moussa, Andrea Krotter, Alba González‐Roz   +4 more
wiley   +1 more source

Associations of cannabis use, tobacco use and co‐use with brain volume: A systematic review and meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cannabis is the most widely used illicit drug worldwide and is often co‐used with tobacco, the leading cause of preventable death. Although cannabis and tobacco have distinct neurobiological actions, their associations with brain volumes are unclear.
Katherine Sawyer, Tom P. Freeman, Martine Skumlien, Esther Walton, Thomas Lancaster, Jorien L. Treur, Valentina Lorenzetti, Anna K. M. Blackwell, Chloe Burke, Richie J. Carr, Constantinos Constantinides, Maisie Cox, Sarah Dance, Shadi Daryan, Sorcha Hamilton, Tom Jenkins, Gemma M. J. Taylor   +16 more
wiley   +1 more source

Diagnostic validity of Addictions Neuroclinical Assessment indices for alcohol use disorder: Findings from an observational case–control study

Addiction, EarlyView.
Abstract Background and aims The Addictions Neuroclinical Assessment (ANA) provides a framework for assessing alcohol use disorder (AUD) with indices that may be both mechanistically and diagnostically informative. This study evaluated an array of measures from the three ANA domains in relation to AUD diagnostic status. Design This cross‐sectional case–
Molly L. Garber, Carly McIntyre‐Wood, Mahmoud Elsayed, Michael T. Amlung, Lawrence H. Sweet, James MacKillop   +5 more
wiley   +1 more source

Misuse of prescription medicines is as prevalent as the use of recreational drugs and novel psychoactive substances in Singapore: an unrecognised public health issue? [PDF]

Singapore Med J, 2022
Chan WL, Dargan PI, Haynes CM, Green JL, Black JC, Dart RC, Wood DM.   +6 more
europepmc   +1 more source

Temporal and geographical patterns of nitazene detections in drug samples and biospecimens in the United States, 2019–2024

Addiction, EarlyView.
Abstract Background and aims Nitazenes are a novel subclass of synthetic opioids that have been increasingly implicated in the United States (US) overdose crisis. Despite their growing presence in the illicit drug supply, national trends have not been systematically evaluated.
David T. Zhu, Nicole D. Fitzgerald, Joseph J. Palamar, Alex J. Krotulski   +3 more
wiley   +1 more source